All In Biotech

Drug Trial Radar · NCT05107674

A Study of NX-1607 in Adults With Advanced Malignancies

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types

Last checked: Nov 19, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

345

Planned (sponsor's estimate)

Start

Sep 29, 2021

Primary completion

Aug 31, 2026

Study completion Feb 28, 2028

Sponsor

Lead sponsor
Nurix Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

Conditions

  • Ovarian Cancer, Epithelial
  • Gastric Cancer
  • GastroEsophageal Junction (GEJ) Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Metastatic or Unresectable Melanoma
  • Non-small Cell Lung Cancer (NSCLC)
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Malignant Pleural Mesothelioma (MPM)
  • Triple Negative Breast Cancer (TNBC)
  • Metastatic Urothelial Carcinoma
  • Cervical Cancer
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Richter Transformation
  • Microsatellite Stable Colorectal Carcinoma

Interventions

  • NX-1607Drug

    Oral NX-1607

  • PaclitaxelDrug

    Paclitaxel IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEsTime frame: 16 months
  2. Incidence of immune-related AEs (irAEs), all deaths, and dose-limiting toxicities (DLTs)Time frame: Up to 2 Years
  3. Objective Response Rate (ORR) per disease-specific response criteria as assessed by the InvestigatorTime frame: Up to 3 Years

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Completed

  • University of Southern California

    Los Angeles, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • University of Colorado School of Medicine

    Aurora, Colorado · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • University of North Carolina

    Chapel Hill, North Carolina · Recruiting

  • University of Oklahoma

    Oklahoma City, Oklahoma · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Virginia

    Charlottesville, Virginia · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Addenbrookes Cambridge University Hospital

    Cambridge, United Kingdom · Recruiting

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom · Recruiting

  • Sarah Cannon Research Institute

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

  • Northern Centre for Cancer Care

    Newcastle, United Kingdom · Recruiting

  • Churchill Hospital

    Oxford, United Kingdom · Completed

  • Royal Marsden Hospital NHS Foundation Trust

    Sutton, Surrey, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.